title: The development of sarcoidosis with the use of alemtuzumab - clues to T-cell immune reconstitution.
authors.forename: Jecko
authors.initials: J
authors.lastname: Thachil
authors.forename: Vittal
authors.initials: V
authors.lastname: Jadhav
authors.forename: Manish
authors.initials: M
authors.lastname: Gautam
authors.forename: Steve
authors.initials: S
authors.lastname: McKew
authors.forename: Arvind
authors.initials: A
authors.lastname: Arumainathan
authors.forename: Daniel
authors.initials: D
authors.lastname: Collins
authors.forename: Colin
authors.initials: C
authors.lastname: Smyth
authors.forename: Janice
authors.initials: J
authors.lastname: Harper
authors.forename: Andrew
authors.initials: A
authors.lastname: Pettitt
mesh_terms: D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D016516:CD4-CD8 Ratio; D006801:Humans; D008297:Male; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000188:drug therapy / Q000276:immunology; D012507:Sarcoidosis / Q000209:etiology* / Q000276:immunology; D012878:Skin Neoplasms / Q000188:drug therapy / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab